Drug Discovery 2022
This year, Drug Discovery 2022 promises to provide a platform for the whole drug discovery community to meet in-person in London. ELRIG has partnered with; BPS, SLAS, and RSC to draw together an exciting and progressive 2-day event containing; cutting-edge advancements in screening, automation and high content imaging, and innovations in disease models, advances in cell and gene therapies, revolutions through partnerships, future perspectives in medicinal and green chemistry and finally creative thinking to deliver therapies to one of the most challenging diseases facing society; COPD.
Find our involvement through the scientific program and below, and don't forget to visit us in-person at booth #C5.
|Session: Innovation through partnership - Sponsored by AstraZeneca Open Innovation|
Wednesday, October 5th ,12:35
Beyond small molecules ... Diversity in drug modalities
Dave Madge, PhD, Vice President, WuXi AppTec
As companies strive to identify the most efficacious hits against a range of different targets, many companies, in addition to traditional small molecule approaches and exploring other modalities such as oligopeptides, peptides, drug conjugates, in their quest to produce the “best” drugs. This presentation explores a range of non-small molecule modalities and their role in drug discovery today.
|Dr. Dave Madge, Vice President of Discovery Services, WuXi AppTec|
Dr. Nick Camp, Project Manager and Medicinal Chemistry Advisor, WuXi AppTec
Ambreen Anwer, Business Development Manager, WuXi AppTec